Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Divestment

- PMLiVE

Combining therapies and combining research

The strategy for retaining antibiotic security

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

- PMLiVE

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

CNS penetration could give edge over rival

- PMLiVE

Bicycle Therapeutics to tackle AMR with government funding

Biotech to discover new class of antibacterial agents

- PMLiVE

GSK gets serious about immunotherapy with Merck deal worth up to $4.2bn

Partners to co-develop novel bifunctional fusion protein

- PMLiVE

Advair generics and acquisitions to hit GSK in 2019

Earnings to decline as company transforms

- PMLiVE

GSK’s Advair Diskus faces first generic in US

Analysts predict around $250m in sales for Wixela Inhub this year

- PMLiVE

GSK and Sanofi join Finland’s 500,000 genomics study

AstraZeneca, MSD and Pfizer already participating

- PMLiVE

GSK upbeat on its return to oncology market

Zejula signals comeback after four year hiatus

- PMLiVE

AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

Underlines importance of cancer drugs to company's future growth

- PMLiVE

First-line ovarian approval cements AZ’s Lynparza lead

Also new data on recently approved kidney disease drug

- PMLiVE

GSK and Pfizer to create combined consumer health titan

Spin-out will allow GSK to focus on prescription drugs and vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links